Breast Cancer; TNBC - Triple-Negative Breast Cancer; HER2-negative Breast Cancer
—
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships Vidya: lead asset acquired in Vidya Acquisition (Jul 2026); $200M concurrent private placement funds operations into H2 2029
Indications
Food allergy(Phase 2)
Chronic spontaneous urticaria (CSU)(Phase 2)
Relapsing multiple sclerosis (RMS)(Phase 2)
Catalysts
— second half of 2027
— first half of 2028
— second half of 2028
Status note Majority of resources now focused on VT-7208; Phase 2 proof-of-concept studies being initiated in food allergy and CSU.
PCS6422
Phase 2 · Terminated
Aliases NGC-Cap (PCS6422 + capecitabine)
Target DPD
Partnerships Elion Oncology: license terminated and program returned to Elion (settlement Jul 23, 2026); Processa paid $650k and agreed to grant Elion a 7.5% non-voting equity interest
Indications
Advanced/metastatic breast cancer(Phase 2)
Status note Ongoing NGC-Cap Phase 2 trial being closed following termination of the Elion license agreement and return of the program to Elion.
PCS499
Stage not disclosed · Active
Status note Legacy pharmaceutical asset; development being evaluated, including strategic opportunities to maximize long-term value.
PCS12852
Stage not disclosed · Active
Target 5-HT4 receptor (5HT4 agonist)
Status note Legacy pharmaceutical asset; development being evaluated, including strategic opportunities to maximize long-term value.
PCS11T
Stage not disclosed · Active
Target topoisomerase I (SN38 analog)
Status note Legacy pharmaceutical asset; development being evaluated, including strategic opportunities to maximize long-term value.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Breast Cancer; TNBC - Triple-Negative Breast Cancer; HER2-negative Breast Cancer
—
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.